Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a ...

Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

Netherlands-based diagnostics imaging company Royal Philips announced the enrolment of its first patient in the US THRO IDE ...

Interventional cardiologist Dr. Ross Melvin joins us to give a demonstration of the new technology available to treat peripheral arterial disease.

Impaired blood circulation in the lower limbs is a common health problem among the elderly and one of the most prominent ...

US-based bioabsorbable scaffold company R3 Vascular has been granted investigational device exemption (IDE) approval by the ...

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its drug-eluting ...

November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE ... eluting bioresorbable scaffold for treating below-the-knee (BTK) peripheral ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

R3 Vascular, has been granted investigational device exemption (IDE) approval by the US Food and Drug Administration (FDA) to launch its ELITE-BTK pivotal trial of its peripheral arterial disease ...